Prime Medicine Inc (PRME) concluded trading on Thursday at a closing price of $1.24, with 0.46 million shares of worth about $0.57 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -67.11% during that period and on April 17, 2025 the price remained unchanged. Currently the company’s common shares owned by public are about 131.16M shares, out of which, 51.92M shares are available for trading.
Stock saw a price change of 5.98% in past 5 days and over the past one month there was a price change of -38.00%. Year-to-date (YTD), PRME shares are showing a performance of -57.53% which decreased to -76.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.12 but also hit the highest price of $8.27 during that period. The average intraday trading volume for Prime Medicine Inc shares is 1.31 million. The stock is currently trading -21.98% below its 20-day simple moving average (SMA20), while that difference is down -39.94% for SMA50 and it goes to -63.88% lower than SMA200.
Prime Medicine Inc (NASDAQ: PRME) currently have 131.16M outstanding shares and institutions hold larger chunk of about 31.23% of that.
The stock has a current market capitalization of $162.64M and its 3Y-monthly beta is at 2.15. It has posted earnings per share of -$1.70 in the same period. It has Quick Ratio of 5.58 while making debt-to-equity ratio of 0.27. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRME, volatility over the week remained 9.66% while standing at 11.66% over the month.
Stock’s fiscal year EPS is expected to rise by 27.26% while it is estimated to increase by 5.27% in next year. EPS is likely to grow at an annualized rate of 12.59% for next 5-years, compared to annual growth of -124.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on December 10, 2024 offering a Mkt outperform rating for the stock and assigned a target price of $10 to it. Coverage by H.C. Wainwright stated Prime Medicine Inc (PRME) stock as a Buy in their note to investors on May 20, 2024, suggesting a price target of $10 for the stock. On May 16, 2024, Citigroup Upgrade their recommendations, while on April 22, 2024, Chardan Capital Markets Initiated their ratings for the stock with a price target of $17. Stock get a Buy rating from TD Cowen on April 08, 2024.
